CombinatoRx to Host Analyst Briefing at 8:30 am EST on January 31st, 2006; Presentations to Focus on 2006 Business Outlook.BOSTON -- CombinatoRx, Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRXX) today announced that it will host its inaugural Analyst Briefing on Tuesday, January 31, 2006 at 8:30 am EST EST electroshock therapy. EST abbr. electroshock therapy at the Millennium Broadway Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . A series of presentations will highlight CombinatoRx's technology platform, business development strategy and upcoming clinical data presentations, in addition to providing financial guidance for 2006. Speakers from CombinatoRx's executive management team include Alexis Borisy, CombinatoRx's Founder, President and Chief Executive Officer; Robert Forrester, Chief Financial Officer; Jan Lessem, Chief Medical Officer; Curtis Keith, CombinatoRx's Founder and Senior Vice President of Research; and Daniel Grau, Senior Vice President of Commercial Operations. The Analyst Briefing can be accessed via live webcast on January 31, starting at 8:30am EST by visiting www.combinatorx.com. The audio link, as well as a downloadable form of the presentation, will be available by visiting the link "Investor Presentations" located under the Investor portion of the CombinatoRx website. Please log on 5-10 minutes before the presentations begin to ensure connectivity. The presentation will be available via web archive for at least 60 days. The briefing will also be available via teleconference at 800-638-5439 passcode 50089238 (domestic) and 1-617-614-3945 passcode 50089238 for international participants. Audio replay will be available all day on January 31st and will begin approximately two hours after the briefing. You may access the replay at 888-286-8010 passcode 66355706 (domestic) and 1- 617-801-6888 passcode 66355706 (international). The Analyst Meeting is open to members of the professional investment community. For information on attending the analyst event, please contact Marli Giannini at 617.425.7018 or mgiannini@combinatorx.com. About CombinatoRx CombinatoRx, Incorporated is a biopharmaceutical company focused on developing new medicines built from synergistic synergistic /syn·er·gis·tic/ (sin?er-jis´tik) 1. acting together. 2. enhancing the effect of another force or agent. syn·er·gis·tic adj. 1. combinations of approved drugs In the United States, the FDA approves drugs. Before a drug can be prescribed, it must undergo an extensive FDA approval process. This process involves first testing the drug on animals or in medical labs. , designed to attack disease on multiple fronts. CombinatoRx applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immunoinflammatory disease, oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. , metabolic disease metabolic disease, n a disorder that causes dysfunction of the metabolic action of the body, resulting in loss of control of homeostasis. paraneoplastic syndrome , neurodegenerative disease Neurodegenerative disease A disease in which the nervous system progressively and irreversibly deteriorates. Mentioned in: Amnesia , and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. . By applying our proprietary screening technology, we have discovered and advanced into clinical trials a portfolio of seven product candidates targeting multiple diseases. For further information, please visit the CombinatoRx website at www.combinatorx.com. Forward-Looking Statement forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 concerning CombinatoRx, its plans for its product candidates and collaborations, its drug discovery technology, its financial and clinical results and corporate development. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven unproven Dubious, nonscientific, not proven, quack, questionable, unscientific adjective Relating to that which has not been validated by reproducible experiments or other scientific methods for determining effect or efficacy nature of the Company's drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional funding for its research and development and those other risks that can be found in the "Risk Factors" section of CombinatoRx's Registration Statement on Form S-1 on file with the Securities and Exchange Commission. No forward-looking statement can be guaranteed and actual results may differ materially from those CombinatoRx projects. In addition, the forward-looking statements included in this press release represent CombinatoRx's views as of the date of this release. CombinatoRx anticipates that subsequent events and developments will cause its views to change. However, while CombinatoRx may elect to update these forward-looking statements at some point in the future, CombinatoRx specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing CombinatoRx's views as of any date subsequent to the date of this release. (c) 2006 CombinatoRx, Incorporated. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion